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Overexpressionof humankynurenine-3-monooxygenase
protects against 3-hydroxykynurenine-mediated
apoptosis through bidirectional nonlinear feedback
K Wilson1, M Auer2, M Binnie1, X Zheng3, NT Pham2, JP Iredale3, SP Webster1 and DJ Mole*,3
Kynurenine 3-monooxygenase (KMO) is a critical regulator of inflammation. The preferred KMO substrate, kynurenine, is
converted to 3-hydroxykynurenine (3HK), and this product exhibits cytotoxicity through mechanisms that culminate in apoptosis.
Here, we report that overexpression of human KMO with orthotopic localisation to mitochondria creates a metabolic environment
during which the cell exhibits increased tolerance for exogenous 3HK-mediated cellular injury. Using the selective KMO inhibitor
Ro61-8048, we show that KMO enzyme function is essential for cellular protection. Pan-caspase inhibition with Z-VAD-FMK
confirmed apoptosis as the mode of cell death. By defining expression of pathway components upstream and downstream of
KMO, we observed alterations in other key kynurenine pathway components, particularly tryptophan-2,3-dioxygenase
upregulation, through bidirectional nonlinear feedback. KMO overexpression also increased expression of inducible nitric oxide
synthase (iNOS). These changes in gene expression are functionally relevant, because siRNA knockdown of the pathway
components kynureninase and quinolinate phosphoribosyl transferase caused cells to revert to a state of susceptibility to 3HK-
mediated apoptosis. In summary, KMO overexpression, and importantly KMO activity, have metabolic repercussions that
fundamentally affect resistance to cell stress.
Cell Death and Disease (2016) 7, e2197; doi:10.1038/cddis.2016.87; published online 14 April 2016
The kynurenine pathway is the main route of tryptophan
(TRP) metabolism in mammals (Figure 1). Kynurenine
3-monooxygenase (KMO) is a flavoprotein hydroxylase
enzyme that catalyses the conversion of kynurenine (KYN)
to 3-hydroxykynurenine (3HK) in the kynurenine pathway.
KMO is an important therapeutic target for multiple organ
dysfunction, particularly that triggered by acute pancreatitis
and the systemic inflammatory response,1,2 and for Hunting-
ton’s disease.3 KMO also has a significant role in the immune
adaptive response.4 TRP is converted to KYN by tryptophan-
2,3-dioxygenase (TDO) and indoleamine-2,3-dioxygenases
(IDOs), following which KYN has several potential fates. The
majority of KYN is metabolised by KMO to 3HK. KYN is also a
substrate for kynurenine aminotransferase 1 and 2 (KAT1 and
KAT2) to form kynurenic acid (KYNA). KYNA is sedative and
neuroprotective, acting at GABA (γ-aminobutyric acid) recep-
tors. Hypothetically, KYN may also be directly converted to
3-hydroxyanthranilic acid (3HAA) but most 3HAA is produced
by the oxidation of 3HK by 3-hydroxyanthranilic acid oxidase
(3HAO). 3HAA is subsequently metabolised to quinolinic acid
(QUIN), which is injurious to cells, especially neurons, via a
mechanism of NMDA-mediated excitotoxicity.5 The kynure-
nine pathway culminates in the production of nicotinamide
adenine dinucleotide (NAD).4
Increased kynurenine metabolite levels have been impli-
cated in many disease states, particularly in neurodegenera-
tive and inflammatory disorders. In particular, the KMO
product, 3HK, is a free radical generator that exhibits
toxicity to cells through reactive oxygen species generation,
crosslinking of proteins and mitochondrial respiratory chain
inhibition.6 3HK has recently been identified in a metabolomic
screen of brain tissue extracts in Parkinson’s disease.7
Therefore, because systemic inflammatory disease states
are associated with increased flux through the kynurenine
pathway1,8 and because we and others have previously
observed 3HK-mediated cytotoxicity in vitro we wanted
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to investigate whether increased expression of KMO in a
mammalian system affects the cell death response to 3HK,
and, if so, to explore the potential underlying mechanisms.
To address this question we overexpressed KMO in
HEK293 cells and imaged the subcellular localisation of
overexpressed KMO. The cell death response to exogenous
3HK was then evaluated by three separate measures of
cytotoxicity and subsequently confirmed by direct visuali-
sation using time-lapse confocal fluorescence microscopy of
cells overexpressing a fluorescent KMO fusion protein. To
define whether altered sensitivity to 3HK-mediated cell death
was dependent on KMO activity we used the potent KMO
inhibitor Ro61-8048. We measured the effect of KMO over-
expression on upstream and downstream kynurenine
pathway enzyme expression and evaluated the functional
relevance of gene silencing using siRNA knockdown of
specific pathway components. Lastly, we propose a mechan-
ism to explain these observations as our experiments
show that KMO-overexpressing cells undergo bidirectional
adaptation via alteration of kynurenine pathway
homoeostasis.
Results
Human KMO stably expressed in HEK293 cells is
enzymatically active and co-localises to the mitochon-
dria. KMO detected with anti-V5-Dylight650 antibody was
localised in the cytoplasm in the perinuclear region of the
cell consistent with the distribution of mitochondria in cells9
(Figure 2a). Three-dimensional analysis of HEK293-E2-
Crimson-KMO cellular staining images verified co-localisation
of KMO to the mitochondria (stained with MitoGreen;
PromoKine, Heidelberg, Germany) (Figure 2b) with a sig-
nificant Pearson correlation coefficient of 44.2%. This correla-
tion result indicates a strong positive relationship between the
localisation of the mitochondria and KMO in these cells.
Full-length KMO(V5-6His) demonstrated enzymatic activity
in the cell lysate with a Km for NADPH of 20±6.7 μM and a Km
for L-kynurenine of 86± 18.5 μM (Figure 2c and d).
KMO-overexpressing cells are protected from 3HK-
mediated toxicity as a function of KMO activity. Time-
lapse bright-field microscopy of stably transfected HEK293-
KMO(V5-6His) cells did not show any changes in baseline
Figure 1 The kynurenine pathway of tryptophan metabolism with the KMO catalytic reaction indicated in blue
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cell death when unchallenged. However, and in keeping with
our previous observations of 3HK-mediated cytotoxicity,1
addition of 500 μM 3HK caused cell death in wild-type
HEK293 cells (Figure 3a–d and Supplementary Video 1).
Interestingly, overexpression of KMO protected cells against
3HK-mediated cytotoxicity when quantified by measuring
LDH release into the cell culture media (Figure 3b). Cell
death was preceded by a loss of mitochondrial transmem-
brane potential demonstrated by DiOC6 staining (Figure 3d)
and measured using the intravital dye JC-1 (Figure 3a).
Again, protection against 3HK-mediated mitochondrial injury
was conferred by overexpression of KMO. Furthermore,
caspase activity was significantly increased in cells exposed
to 3HK (Figure 3c), confirming activation of canonical
apoptosis pathways, but this activation was much less
pronounced in KMO-overexpressing cells compared with
non-transfected HEK293 control cells. Moreover the cytopro-
tective effect was abrogated by addition of the potent KMO
inhibitor Ro61-804810 (Figure 3a–d), thus establishing that
overexpressed KMO must be functional to be protective.
Addition of the pan-caspase inhibitor Z-VAD-FMK decreased
the disruption of mitochondrial transmembrane potential
measured by DiOC6 further validating the mode of 3HK-
induced cell death as apoptosis (Figure 3d).
In order to prove that (i) the protective effect of over-
expressing KMO was proportional to the amount of KMO
activity and, (ii) that protection was conferred at the level of the
individual cell rather than on an ambient or bystander effect in
an entire cell culture, HEK293 cells were transiently trans-
fected with the 10His-E2-Crimson-KMO fusion protein and
visualised by confocal time-lapse microscopy. Transient
transfection resulted in a range of E2-Crimson-KMO over-
expression in cells in a single-culture vessel, allowing the
visual comparison of E2-Crimson fluorescence intensity (and
therefore KMO activity) between cells to act as an internal
control within one culture vessel. Cells variably expressing
E2-Crimson-KMO were incubated with 500 μM 3HK and
studied under time-lapse conditions. Cells with lower
E2-Crimson fluorescence intensity, and therefore lower KMO
activity, were markedly more susceptible to 3HK-mediated
cytotoxicity, undergoing apoptosis sooner than cells in the
same culture which had high overexpression of E2-Crimson-
KMO (Figure 4 and Supplementary Video 1).
Taken together, these data show that overexpression of
KMO protects against 3HK-mediated cell death and that KMO
enzyme activity is both necessary and proportionate to that
protection.
Overexpression of KMO alters endogenous kynurenine
pathway homoeostasis. One possible explanation for the
observation that overexpression of KMO confers resistance
to 3HK-mediated cell death is that cells which overexpress
Figure 2 Expression of active mitochondrial localised KMO. (a) Cellular staining image indicating mitochondrial localisation of KMO in HEK-KMO(V5-6His) cells obtained
using the Opera HCS system with a × 40 water immersion objective (NA 0.9). Antibody-labelled KMO was detected using the 640 nm laser (2000 μW, 40 ms exposure time,
emission filter 690/70), nuclear staining was detected using the UV light source (365 nm excitation, 40 ms, emission filter 450/50) and the 488 nm laser (1250 μW, 280 ms,
emission filter 520/35) was used to detect the cell membrane stain. The white scale bar corresponds to 10 μm. (b) 3D image of KMO-expressing cells obtained using the Leica
SP5C spectral confocal laser scanning microscope. The argon (488 nm) laser was used for detection of mitochondria and the 633 nm laser for detection of KMO confirming co-
localisation. The white scale bar corresponds to 10 μm. Steady-state kinetics are shown for KMO at 37 °C, pH 7.0. Starting concentrations of (c) NADPH and (d) L-kynurenine are
plotted versus 3HK produced and data fitted to the Michaelis–Menten equation (Y= Bmax*X/(Kd+X) using GraphPad Prism4 software
Protection via KMO against 3HK-mediated apoptosis
K Wilson et al
3
Cell Death and Disease
HEK-
wt
HEK-
KMO
HEK-
wt
HEK-
KMO
Time 0 h control ZVAD K3 control ZVAD K3 Time 3 h control ZVAD K3 control ZVAD K3
0 10 10 0 10 10 0 10 10 0 10 10
3HK
0
7054.5 7356.5 7541 7211.5 7347.5 7362
3HK
0
7091.5 6936 6938 7134.5 6856 6915.5
10
7061 7411 7530.5 7447 7069.5 7509.5
10
5579.5 6225 6225 6790 6828 5685.5
100
6869 7413.5 7146 7028 6963 7216
100
4949 6204.5 5151 6576 7139 5278
500
6871.5 7351 7180 6810.5 7232.5 7322.5
500
4527.5 5858.5 4605 5689 6567.5 4371
Staurosporine 300
7049.5 7469 7361.5 7309.5 6954.5 7165.5
Staurosporine 300
2741 5987.5 2227 2889.5 6309.5 2722.5
HEK-
wt
HEK-
KMO
HEK-
wt
HEK-
KMO
Time 6 h control ZVAD K3 control ZVAD K3 Time 24 h control ZVAD K3 control ZVAD K3
0 10 10 0 10 10 0 10 10 0 10 10
3HK
0
6921.5 6901.5 6888.5 6852.5 6811 6868.5
3HK
0
7187 6824.5 6873.5 7037 6744 6882
10
5357.5 5900.5 5481.5 6619.5 6792 5669
10
4434.5 6418.5 4518 5805.5 6602.5 4466
100
4543.5 5596 4801.5 5665 6705 4699
100
3281.5 6121 3068 4908.5 6388 3696.5
500
4185.5 4976 3973 5152 6064.5 4175.5
500
1913.5 5188.5 1932.5 3662.5 6294 2290
Staurosporine 300
2162.5 4006.5 2150.5 2062 4370.5 1954
Staurosporine 300
1188.5 3621 1079.5 981 3233.5 1145
7500 900
Mean DIOC6 value
Figure 3 KMO protects against 3HK-induced cell death. Graphs showing (a) JC-1 readout, n= 6 for each cell type and conditions, red:green ratio is significantly decreased
(P= 0.0498) in wild-type cells incubated with 3HK compared with KMO cells, (b) LDH assay readout, n= 6 for each cell type and conditions, LDH release is significantly
increased (P= 0.0016) in wild-type cells incubated with 3HK compared with KMO cells, (c) caspase 3/7 activity readout, n= 6 for each cell type and conditions, caspase activity is
increased in wild-type cells incubated with 3HK compared with KMO cells. The S.E.M. is indicated by error bars on all graphs. Data are representative of three independent
experiments for each of these assays. (d) Heat maps indicating DiOC6 staining in KMO cells verses wild-type cells with a 3HK-dose and time response in the presence and
absence of Z-VAD-FMK, data are mean values of n= 2 for each cell type and conditions from one independent experiment
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KMO are capable of rapid elimination of 3HK from the
ambient medium. Therefore, we measured the rate of
disappearance of 3HK from the medium in KMO-
overexpressing cells compared with controls. When incu-
bated with HEK-KMO(V5-6His) cells, 3HK concentration in
the medium reduced in a time-dependent manner at a much
faster rate than in wild-type HEK293 cell cultures, indicating
more rapid clearance, sequestration or metabolism of 3HK
(Figure 5a).
To investigate further whether increased flux through the
kynurenine pathway observed in HEK-KMO(V5-6His) cells
resulted from a global increase in kynurenine pathway enzyme
expression, we measured mRNA expression of upstream and
downstream components in HEK-KMO(V5-6His) cells com-
pared with wild-type control cells. KMO-overexpressing cells
showed significantly increased TDO mRNA expression (30-
fold). HAAO (3-hydroxyanthranilate 3, 4-dioxygenase) and
QPRT (quinolinate phosphoribosyl transferase) mRNA
expression were also elevated (Figure 5b). Interestingly,
although IDO1 is expressed at low levels in HEK cells, no
increase in expression accompanied increased flux through
the pathway, and IDO1 expression did not increase in line with
increased TDO expression. KYNU (kynureninase), KAT1
(kynurenine amino transferase-1), KAT2 and KAT3 expression
were not significantly altered.
Overexpression of KMO increases iNOS expression. It is
known that 3HK acts as a free radical donor, therefore the
increased substrate flux through KMO and resultant increase
in 3HK production was investigated as a potential oxidative
stressor. Inducible nitric oxide synthase-2 (iNOS) mRNA
expression was measured as an indicator of oxidative stress.
iNOS expression was increased 3.25-fold in KMO-
overexpressing cells compared with controls (Figure 5b).
siRNA knockdown of KYNU and QPRT in KMO-
overexpressing cells restores susceptibility to
3HK-mediated cell death. To determine whether the altera-
tions in pathway enzyme gene expression were functionally
relevant to the observed protection from 3HK-mediated
cytotoxicity, we used siRNA knockdown, singly and in
combination, for the kynurenine pathway components listed
in Figure 6. Knockdown efficiencies for each gene targeted
are shown in Figure 6b. Vehicle only control incubations
(containing Lipofectamine RNAiMAX) caused a small
increase in susceptibility to 3HK-mediated cytotoxicity. How-
ever, a significant further increase in susceptibility to 3HK
was seen after siRNA knockdown of kynureninase (KYNU)
and QPRT. siRNA knockdown of TDO and HAAO showed no
difference in 3HK-mediated cytotoxicity compared with
transfection reagent alone. In keeping with these observa-
tions, knockdown of all four pathway components simulta-
neously confirmed the phenotypic effect of KYNU and QPRT
knockdown alone, but did not show any additive effect.
Together, these data confirm that the alterations in kynur-
enine pathway enzyme mRNA expression are a functional
component of the mechanism by which KMO overexpression
affords protection against 3HK-mediated cytotoxicity.
Discussion
KMO is a critical component of the kynurenine pathway of
tryptophan metabolism and an important regulator of inflam-
mation. In this series of experiments, we demonstrate that
overexpression of human KMO with orthotopic localisation to
mitochondria creates a metabolic environment, in which the
cell is resistant to exogenous 3HK-mediated cellular injury.
Using a potent KMO inhibitor we show that protection depends
on KMOenzyme function and further substantiate this concept
by directly visualising 3HK-mediated death in cells with low or
Figure 4 Time-lapse confocal microscopy images of HEK293 cells transiently transfected with 10His-E2-Crimson-KMO (red) incubated with 500 μM 3HK in the presence of
Annexin-V-Fluos (green) showing low or non-KMO-expressing cells undergoing apoptosis more rapidly than high-expressing cells. The black scale bar corresponds to 10 μm
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no expression of KMO and increased tolerance to exogenous
3HK in high KMO-expressing cells in a single-culture system.
Therefore, we have shown that the protective effect of KMO
overexpression is directly proportional to the amount of active
KMO present in any individual cell. KMO overexpression and
protection was accompanied by an increased elimination of
3HK from ambient culture medium. Cells with increased KMO
activity also showed transcriptional upregulation of the
upstream enzyme TDO and the downstream kynurenine
pathway components HAAO and QPRT. These changes, in
particular KYNU and QPRT upregulation, were shown to be
more than associative observations because siRNA knock-
down of KYNU and QPRT restored susceptibility to 3HK-
mediated cell death in HEK-KMO cells.
KMO is localised to the outer mitochondrial membrane due
to the presence of a large membrane targeting domain at its
C-terminus.11 The tissue distribution of KMO is largely in liver
and kidney, but lower expression is found in brain, especially
microglial cells and macrophages. Artificial overexpression of
human KMO protein has been reported in the following cell
lines: HEK293,12 COS-1 (ref. 13) and CHO cells.14 Winkler
et al.14 reported localisation of exogenous human KMO to the
mitochondria in CHO cells using immunohistochemistry.
Congruent with this, cell-staining experiments reported herein
show detection of KMO staining around the nucleus of the cell
(Figure 2a). This is consistent with the perinuclear mitochon-
drial distribution in the cell9 and indicates that recombinant
expression of human KMO in these cells mimics localisation
observed in natural cells. 3D imaging analysis confirmed co-
localisation of KMO to the mitochondria with a significant
Pearson correlation coefficient of 44.2%. KMO demonstrated
good enzymatic activity (Figure 2c and d) when prepared in a
cell lysate that was comparable to previously reported kinetic
characterisation of the human enzyme.13
Figure 5 Quantification of exogenous 3HK and KMO mRNA levels. (a) Plot
showing 3HK concentration remaining in each cell and control incubation plotted
against incubation time, n= 4, the S.E.M. is indicated by error bars on the plot, data
are representative of two independent experiments. (b) Table showing relative
quantification of mRNA levels corresponding to each kynurenine pathway enzyme in
HEK-KMO and HEK293 cells as determined by RT-qPCR
Figure 6 siRNA knockdown of the kynunenine pathway. (a) Graph showing cell
death response indicated by LDH assay, n= 2 for each knockdown conditions, the S.
E.M. is indicated by error bars on the graph, data are from one independent
experiment, knockdown of QPRT causes a significant increase (P= 0.0077) in cell
death as does knockdown of all four genes (P= 0.0194). (b) Table showing the
averaged knockdown efficiency for each gene in the cells
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3HK is an oxidative stress generator that releases free
hydroxyl radicals inducing cellular apoptosis.15 3HK sensitivity
varies between tissue/cell types and differential uptake of 3HK
by cells is believed to be responsible.16Wei et al.16 tested 3HK
toxicity against three neuronal cell types and found all three to
be sensitive to high pharmacological doses of 3HK with at
least 90% cell loss at a concentration of 500 μM. KMO-
overexpressing cells demonstrated reduced cell death at this
concentration than wild-type HEK293 cells (Figure 3). In order
to define the requirement for KMO enzyme activity to confer
protection, Ro61-8048, a known KMO inhibitor,10 was used for
the duration of the 3HK incubation to define KMO activity
dependence in these cells. KMO blockade restored sensitivity
to 3HK-mediated cell death to a level similar to that of the wild-
type cells. Three measures of cytotoxicity were used, namely
membrane depolarisation, plasma membrane rupture and
initiation of apoptosis were used to validate this result
(Figure 3a). Detection of caspases 3 and 7 activity in cell
lysates and a reduction in cell death response following pan-
caspase inhibition confirms that the mechanism of 3HK-
mediated cell death is apoptosis, as previously indicated in the
literature.16,17
Exogenous 3HK concentration decreased steadily over
time in KMO-overexpressing cells but not in the HEK293 wild-
type incubation and in the cell-free controls, indicating
increased metabolism or clearance of 3HK. This adaptation
offers a potential explanation for altered sensitivity to 3HK-
mediated cell death in KMO-overexpressing cells.
Metabolism of 3HK necessitates expression of the enzymes
downstream of KMO in the kynurenine pathway. The mRNA
levels corresponding to the genes for the KP enzymes were
quantified for each cell type and used as a surrogate indicator
of protein expression. mRNA levels corresponding to KMO
were 7000 times higher in the transfected cells than in the wild-
type cells. HEK293 cells express KMO endogenously and the
other kynurenine pathway enzymes but KMO activity was not
detectable in these cells (data not shown), correlating with the
observations of Alberati-Giani et al.12 Several kynurenine
pathway enzymes demonstrated upregulation in the KMO
cells, in particular, the gene corresponding to TDO. TDO
catalyses the first and rate limiting step in tryptophan
metabolism. TDO upregulation in KMO-overexpressing cells
may imply the existence of a feedback mechanism to enable
homoeostasis of kynurenine concentrations in the cell. Over-
expression of KMO results in increased turnover of kynurenine
to 3HK, it is possible that TDO is upregulated to maintain
kynurenine levels by production of the kynurenine precursor
metabolite N-formylkynurenine. 3-HAAO and QPRT also
demonstrated upregulation. This may contribute to the
decreasing 3HK concentration as these enzymes occur
downstream of KMO in the pathway. A further possible
explanation is that metabolism of 3HK by upregulated HAAO
and QPRT may increase tolerance to 3HK as clearance of
3HK will be more efficient in KMO-overexpressing cells. This
argument is rational and precedented by observations in
several other biological systems that are able to adapt in
response to external stimuli for the maintenance of physiolo-
gical homoeostasis.18 Integral feedback control is an impor-
tant element in ensuring homoeostasis in a variable or
uncertain environment when the surrounding parameters are
imperfect.19 Specifically, in our engineered cell line system, we
have overexpressed KMO protein by 7000-fold. It is therefore
expected that cellular kynurenine levels will be depleted and
3HK levels elevated due to increased KMO activity, although
this was not directly measured.We did show that the upstream
enzyme TDO and downstream enzymes HAAO andQPRTare
upregulated in these cells, and can hypothesise that these
changes are the result of integral feedback control in this cell
system in response to altered kynurenine and 3HK levels.
Increased kynurenine production stimulated by TDO and
increased 3HKmetabolism by HAAO and QPRTmay facilitate
maintenance of a steady-state environment despite KMO
overexpression. Upregulation of the downstream enzymes
may also contribute to reduced 3HK mediated cell death by
3HK metabolism.
The interactome of KMO is not yet established. Of interest in
our paper is the upregulation of iNOS2 mRNA levels in
KMO-overexpressing cells. Elevated levels of the reactive nitric
oxide free radical NO produced by iNOS2 are associated with
cellular stress.20 KMO is pro-apoptotic due to its production
of free radical generating 3HK.17 Whilst the results described
here support reduced 3HK-mediated cell death in KMO-
expressing cells, increased production of 3HK may induce
cellular stress indicated by upregulated iNOS2. In addition,
production of neurotoxic quinilonic acid may contribute to this
cellular stress as a result of upregulated HAAO expression.
It was important to determine that the altered cell death
response resulted from KMO expression and activity rather
than upregulation of other kynurenine pathway enzymes. TDO
and three enzymes downstream of KMO were downregulated
by siRNA knockdown before incubation with 3HK. Knockdown
of TDO and HAAO showed no effect on the cell death
response to 3HK. mRNA levels corresponding to KYNU
expression were not upregulated following overexpression of
KMO in HEK293 cells indicating that 3HK can be sufficiently
metabolised by KYNU and the KATenzymes at baseline levels
in these cells. However, knockdown of KYNU gene expression
(the enzyme directly downstream of KMO) resulted in
increased 3HK-mediated cell death. Since KYNU is placed
in the main and primary branch of the kynurenine pathway,
knockdown of this enzyme will impact upon 3HK metabolism
enabling accumulation of 3HK. Such alterations to 3HK levels
are consistent with the observation of increased cell death.
This indicates that protection against 3HK-mediated cytotoxi-
city is lost whenmetabolism of 3HK is prevented in these cells.
Knockdown of QPRTalso resulted in increased 3HK-mediated
cell death; however, it is likely that a separate mechanism is
contributory to this finding. Although QPRT metabolises
neurotoxic quinilonic acid to produce NAD as the final step
of the kynurenine pathway and quinilonic acid accumulation in
the cells may contribute to the increased cell death response,
QPRT is also responsible for production of NAD in the
pathways of alanine, aspartate and glutamate metabolism.
Therefore, QPRT knockdown will not only impact on the
kynurenine pathway but also on several other precursor
pathways of NAD synthesis. Prevention of the biosynthesis of
this essential cellular co-factor would result in cell death, as
observed in our experiments.
We have shown that functional KMO overexpression is
responsible for reduced sensitivity to 3HK-mediated cell
Protection via KMO against 3HK-mediated apoptosis
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death. Furthermore, we have shown that functional reversal of
this overexpression with KMO inhibition using a small
molecule inhibitor and prevention of 3HK metabolism by
KYNU siRNA knockdown results in restoration of a normal
3HK-mediated cell death response. We can therefore con-
clude that KMO-overexpressing cells exhibit bidirectional
adaptation through altered kynurenine pathway enzyme
concentrations upstream and downstream of overexpressed
KMO. These adaptations result in the maintenance of
kynurenine and 3HK at an appropriate level in the cell in an
example of robust integral feedback control following a
nonlinear form. Protection from 3HK toxicity appears to be
an important and interesting secondary effect of altered
kynurenine pathway homoeostasis.
Overexpression of KMO in HEK293 cells has allowed the
observation of several KMO-mediated effects and the char-
acterisation of KMO at a cellular level in an engineered
expression system. Whether these KMO-mediated effects are
physiologically relevant in a naturally-regulated or disease-
regulated cell system is now important to determine. In
summary, human KMO overexpression, and importantly
activity, has metabolic repercussions that fundamentally affect
resistance to 3HK-mediated cell stress.
Materials and Methods
Cloning
KMO(V5-6His): Full-length human KMO (GenBank Accession No. NM_003679)
(Cys 452 variant) was amplified from an image clone by Taq polymerase-amplified
PCR. A KOZAK sequence for translational initiation was incorporated by the forward
PCR primer. The native stop codon was removed by the reverse PCR primer. The gene
was ligated into the pcDNA5/FRT/V5/HisTOPO vector (Life Technologies, Renfrew, UK)
by TOPO cloning reaction to facilitate expression by the Flp-In system. The vector
C-terminal V5 and 6 histidine tags were incorporated in the protein construct.
10His-E2-Crimson-KMO: The fusion construct gene 10His-E2-Crimson-KMO
was synthesised by Genscript and provided in vector pUC57. This construct
incorporated a 10 × polyhistidine tag (CATCATCATCACCATCATCATCATCATCAC),
far-red fluorescent protein E2-crimson (sequence obtained from Clontech, CA, USA)
followed by an enterokinase site (GATGACGATGACAAG) and full-length human
KMO (GenBank Accession No. NM_003679, Cys 452 variant). A KOZAK sequence
was incorporated before the start codon for initiation of translation in mammalian
cells. The gene was ligated in to vector pcDNA3.1 (Life Technologies).
Expression
KMO(V5-6His): HEK293 (Flp-In-293 which express lacZ-Zeocin, Life Technol-
ogies) cells were stably co-transfected with 9 μg of pcDNA5/FRT/V5/HisTOPO DNA
and 18 μg of pog44 plasmid. Pog44 expresses Flp recombinase protein; co-
transfection of pog44 with the gene of interest allows targeted integration into the
mammalian cell genome within a transcriptionally active region. Transfection was
carried out using Lipofectamine 2000 (Life Technologies) in OPTI-MEM medium
(Lonza, Slough, UK). Cells were selected for two weeks using hygromycin B (Sigma
Aldrich, Dorset, UK) at 100 μg/ml to select for the hygromycin resistance gene
contained within the pcDNA5 vector before positive colonies were isolated and
cultured.
10His-E2-Crimson-KMO: HEK293 cells were transiently transfected with
pcDNA3.1-10His-E2-Crimson-KMO plasmid DNA. Transfection was carried out
using Lipofectamine 2000 in OPTI-MEM medium. Cells were used for staining and
time-lapse experiments 24–48 h post transfection.
KMO activity assay: kinetic characterisation: Cell lysates were analysed
for KMO enzymatic activity by measuring the amount of KYN converted to 3HK
detected using liquid chromatography-mass spectrometry (LC-MS/MS). Briefly,
200 μg total protein was incubated with 4 mM MgCl2, 1 mM NADPH and
200 μM L-kynurenine in 20 mM HEPES, pH 7 for 2 h at 37 °C with gentle shaking at
250 r.p.m. in a total assay volume of 100 μl. Samples were added to 500 μl
acetonitrile (containing 25 μg/ml of internal standard, d5-TRP) to terminate activity,
followed by centrifugation at 4000 r.p.m. for 20 min to pellet the precipitate. The
supernatant containing KYN and 3HK was removed, dried under nitrogen, and the
residue re-suspended in 30 : 70 methanol:water with 0.1% formic acid ready for
LC-MS/MS analysis.
For the determination of steady-state kinetic parameters for substrate
L-kynurenine, NADPH was added at a concentration of 2 mM with glucose-6
phosphate (3 mM) and glucose-6 phosphate dehydrogenase (1 unit of enzyme per
assay) to maintain the NADPH concentration. L-kynurenine was added at
concentrations of 2, 1, 0.5, 0.25, 0.125, 0.062, 0.031 and 0.015 mM. For co-factor
NADPH dependence of the enzymatic activity, L-kynurenine was added in excess at a
concentration of 500 μM. NADPH was added at a concentration of 100, 50, 25, 12.5,
6.2, 3.1, 1.5 and 0.75 μM. Assays were performed in duplicate.
LC-MS analysis was carried out using the TSQ Quantum Discovery triple
quadrupole mass spectrometer (Thermo Fisher Scientific, Hemel Hempstead, UK)
using a pentafluorophenyl (PFP) fused pore column (Waters, Hertfordshire, UK), at
40 °C. The injection volume was 10 μl and the flow rate was 500 μl/min. The method
had a run time of 4 min and d5 tryptophan was used as an internal standard. Qualifier
and quantifier peaks were identified for 3HK and for d5 Tryptophan. Data was
acquired and processed using Xcalibur 1.4 and LC Quan 2.0 SP1 (Thermo Scientific,
Leicestershire, UK) software packages.
Staining cells for immunofluorescence. HEK-KMO(V5-6His) cells were
stained in transparent 96-well plates (Whatman, GE Healthcare, Buckinghamshire,
UK). Wheat germ agglutinin Alexa Fluor 488 conjugate (Life Technologies) was
used to stain the plasma membrane of the cells. Cells were then fixed by ten minute
incubation in 3.7% paraformaldehyde diluted in PBS+. Following fixation, cells were
permeabilised (0.1% Triton-X100 in PBS) and blocked (3% BSA in PBS) before
staining for KMO using anti-V5 antibody (Life Technologies) chemically labelled with
DyLight650 (Pierce, Thermo Scientific, Leicestershire, UK). Finally, cells were
incubated with DAPI (Biolegend, CA, USA) to allow nuclear staining.
For z stack imaging, HEK-10His-E2-Crimson-KMO cells were fixed and
permeabilised as above and stained for mitochondria using MitoGreen (PromoKine).
Cellular imaging. Cellular staining images were obtained using the Opera
High Content Screening (HCS) system (Perkin Elmer, Coventry, UK). Anti-V5-
DyLight650-labelled KMO was detected using the 640 nm laser (2000 μW, 40 ms
exposure time, and 690/70 emission filter), DAPI (nuclear) staining was detected
using the UV light source (365 nm excitation, 40 ms exposure time, 450/50
emission filter) and the 488 nm laser (1250 μW, 280 ms exposure time, and 520/35
emission filter) was used to detect the cell membrane stain (wheat germ agglutinin-
Alexa488 conjugate). A 40x water immersion objective (NA 0.9) was used for all
imaging.
Z stack imaging. A Leica SP5C spectral confocal laser scanning microscope
(Leica Microsystems, Milton Keynes, UK) was used to obtain high-resolution Z stack
images for 3D imaging analysis. Co-localisation images were obtained using a × 40
objective Plan-Apochromat oil immersion lens and the Argon (488 nm) and 633 nm
lasers at Nyquist sampling rate. Data was collected using Leica Application Suite
Advanced Fluorescence (LAS AF) software. The images were analysed using
FACSDiva software (BD Bioscience, Oxford, UK) to determine the Pearson
coefficient for co-localisation.
JC-1 assay. Non-transfected HEK293 cells and HEK-KMO(V5-6His) cells were
plated out separately into 96-well plates at 5 × 104 cells per well and incubated
overnight at 37 °C, 5% CO2, 95% O2 in DMEM with 10% FBS, 1% L-glutamine, 1%
penicillin-streptomycin. The next day, tissue culture medium was replaced with
medium containing 500 μM 3HK and 20 μM Ro61-8048 (ref. 10) (Roche, West
Sussex, UK), a potent inhibitor of KMO, on both cell types in triplicate and incubated
overnight for 24 h. Controls consisted of both cell types incubated with 500 μM 3HK
only, 20 μM Ro-618048 only and medium only. After incubation, overnight medium
was replaced with medium containing 10 μg/ml JC-1 dye (Life Technologies) and
cells incubated for 30 min in the dark. JC-1 is a lipophilic cationic dye which is used
as an indicator of cell health. The dye was replaced with fresh medium
before reading fluorescence intensity on the TECAN infinite M1000 plate reader
(Tecan, Reading, UK). The plate was read at excitation 535 nm, emission 590 nm to
determine the red measurement and at excitation 485 nm and emission 530 nm to
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determine the green measurement. Measurements were averaged and the red:
green ratio was determined for each sample. JC-1 dye enters mitochondria and its
colour changes to correspond with membrane potential, changes in membrane
potential are represented by the red:green ratio (red—healthy cells, green—
unhealthy cells).
LDH assay. Non-transfected HEK293 cells and HEK-KMO(V5-His) cells were
plated out and incubated overnight as detailed above. The following day, the cells
were subjected to the same 3HK and Ro61-8048 conditions as described above for
24 h. After incubation, cell supernatants were sampled and LDH activity was
measured. LDH catalyses the reaction between Pyruvate and NADH2 resulting in
the formation of lactate and NAD. Enzyme activity was obtained by measuring the
rate of decrease in absorbance at 340 nm due to the oxidation of NADH2 using a
commercial kit (Alpha Laboratories Ltd., Eastleigh, UK) adapted for use on a Cobas
Fara centrifugal analyser (Roche Diagnostics Ltd). LDH assay is an indicator of
plasma membrane integrity as lactate dehydrogenase is only released and
detectable in the cellular supernatant when cell membranes rupture.
Caspase 3 and 7 activity assay. Non-transfected HEK293 cells and
HEK-KMO(V5-His) cells were plated out and incubated overnight as detailed above.
The following day, the cells were subjected to the same 3HK and Ro61-8048
conditions as described above for 24 h. After incubation, 100 μl of Caspase-glo 3/7
reagent (Promega, WI, USA) was added to each sample well and mixed at 500 r.p.
m. on a plate shaker for 30 s followed by a 2 h incubation at room temperature. The
luminescence in each well was read using the TECAN infinite M1000 plate reader at
OD1 with an integration time of 1 s. Caspases 3 and 7 activity is an indicator of cell
death as these proteins are only activated after apoptosis signalling events have
occurred.21 Caspase 3 and 7 share similar substrate specificity allowing them to be
assayed simultaneously.22
DiOC6 assay. Non-transfected HEK293 cells and HEK-KMO(V5-6His) cells
were plated out separately into 96-well plates at 5 × 104 cells per well and incubated
overnight at 37 °C, 5% CO2, 95% O2 in DMEM with 10% FBS, 1% L-glutamine, 1%
penicillin-streptomycin. Four plates were prepared to represent each time point, i.e.
0, 3, 6 and 24 h. The next day, tissue culture medium was replaced with medium
containing 0, 10, 100 or 500 μM 3HK. The 3HK dose response was incubated in the
presence and absence of Ro61-8048 at 10 μM in concentration and, separately, in
the presence and absence of Z-VAD-FMK (Promega) at 10 μM in concentration.
Staurosporine was applied as a positive control at a concentration of 300 nM. Cells
were incubated at 37˚C, 5% CO2, 95% O2 for the appropriate time, that is, 0, 3, 6 or
24 h. Following incubation, media was removed from the cells and replaced with
PBS containing 100 nM DiOC6 (Thermo Fisher). DiOC6 is membrane dye which is
used to detect mitochondrial membrane potential in live cells. The cells were
incubated for 30 min at 37 °C, 5% CO2, 95% O2 in the dark. PBS containing DiOC6
was removed from the cells and replaced with fresh PBS. Fluorescence intensity
was measured using the TECAN infinite M1000 plate reader (Tecan). The plate was
read at excitation 482 nm and emission 504 nm to detect DiOC6 staining.
3HK Metabolism in whole cells. Non-transfected HEK293 cells and HEK-
KMO(V5-His) cells were plated out separately into 96-well plates at 5 × 104 cells per
well and incubated overnight at 37 °C, 5% CO2, 95% O2 in DMEM with 10% FBS,
1% L-glutamine, 1% penicillin-streptomycin. The following day, the medium on the
cells was replaced with 1.5 mM 3HK diluted in tissue culture medium at a volume of
100 μl per well. Samples were obtained every hour from 0 to 7 h. Controls
consisted of DMEM with 10% FBS, 1% L-glutamine, 1% penicillin-streptomycin and
1.5 mM 3HK incubated in the absence of cells. Each sample was precipitated in
500 μl acetonitrile with 25 μg/ml d5 tryptophan (internal standard for MS method)
and dried down under nitrogen. Samples were re-suspended in 30 : 70 methanol:
water with 0.1% formic acid and mass spectrometry analysis (as described above)
was used to quantify 3HK remaining in each sample.
Transfection of siRNA. HEK-KMO(V5-6His) cells were plated in to six-well
plates at 8 × 105 cells per well and incubated overnight at 37 °C, 5% CO2, 95% O2
in OPTI-MEM medium. The following day, cells were transiently transfected with
siRNA for the genes corresponding to TDO, KYNU, HAAO and QPRT using
Lipofectamine RNAiMAX according to the manufacturer’s protocol. Each siRNA
duplex was transfected both individually and simultaneously. The medium on the
cells was replaced with fresh OPTI-MEM the following day. 48 h post transfection,
OPTI-MEM containing 500 μM 3HK was incubated with the cells for 24 h. The LDH
activity assay was performed on the cell supernatants and RT-qPCR analysis was
used to verify knockdown in the cells.
RT-qPCR analysis: kynurenine pathway enzymes. Non-transfected
HEK293 cells and HEK-huKMO(V5-6His) cells were collected and pelleted by
centrifugation for 5 min at 1000 r.p.m. Tissue culture medium was carefully removed
from the cell pellets. Total RNA was extracted from cell pellets using an RNeasy
Mini kit (Qiagen, Hilden, Germany). One microgram of total RNA was used for first
strand cDNA synthesis using a QuantiTect Reverse Transcription Kit (Qiagen).
Expression of the genes corresponding to the kynurenine pathway enzymes were
determined by real-time PCR. We used inventoried TaqMan assays and the real-
time PCR assay was performed on the StepOne system (Applied Biosystems,
Foster City, CA, USA). The thermal profile was 95 °C for 20 s followed by 45 cycles
of 95 °C for 3 s and 60 °C for 30 s. We performed all assays as duplex reactions
with an endogenous 18S RNA internal control.
Time-lapse bright-field microscopy. HEK-KMO(V5-6His) and HEK293
cells were passaged separately on to 5 ml slide flasks (Nunc, Thermo Scientific,
Leicestershire, UK) at a density of 1 × 105 cells/ml. Cells of each type were
incubated with medium containing either 500 μM 3HK or control medium (no
additives) and incubated overnight for 24 h in a warm room at 37 °C, 5% CO2 at
maximum humidity. A Leica DMIRBE inverted microscope (Leica Microsystems)
situated in the warm room was utilised to obtain images using a × 10 objective lens
at 5 min intervals for 24 h. Images were captured using Leica QWIN software and
composite videos exported using Quicktime player.
Live cell imaging. HEK293 cells were plated out at 1 × 104 cells/ml on poly-D-
lysine-treated coverslips placed in the wells of a six-well plate in OPTI-MEM
medium and incubated overnight for 16 h at 37 °C, 5% CO2. The following day, cells
were transiently transfected with pcDNA-10His-E2-Crimson-KMO plasmid DNA
using lipofectamine 2000 in OPTI-MEM medium. Transfection media was removed
6 h post transfection and replaced with DMEM with 10% FBS, 1% L-glutamine, 1%
penicillin-streptomycin before incubation of the cells for a further 18 h at 37 °C, 5%
CO2. 24 h post transfection, coverslips were transferred to the heated stage of a
Zeiss LSM510 META (Zeiss, Cambridge, UK). Cells were immersed in phenol red-
free OPTI-MEM medium containing 5 mM CaCl2, Annexin-V-FLUOS (Roche) at
1 : 100 dilution (diluted from the ready-to-use stock) and 500 μM 3HK and
incubated at 37 °C, 5% CO2 to allow time-lapse images to be acquired. Images
were obtained using a Plan-Apochromat 63x NA1.4 oil lens with no zoom (resulting
pixel size 147 nm × 147 nm). For visualisation of 10His-E2-Crimson-KMO-expres-
sing cells, the fluorescent E2-Crimson protein was excited at 611 nm and the
emitted light recorded at 646 nm. For visualisation of apoptotic cells, the Annexin V
fluorophore was excited at 488 nm and the emission was recorded using a narrow
emission filter BP 515-565 nm. Cells were incubated for 24 h with a time-lapse of
3 min between image acquisition. Data was collected using the corresponding LSM
5 software program (Zeiss, Oberkochen, Germany).
Statistical analysis. Differences between controls and experimental samples
were analysed using an unpaired Student’s t-test using GraphPad Prism software
(GraphPad Software Inc., CA, USA).
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